NYSE:EW Edwards Lifesciences (EW) Stock Price, News & Analysis $88.81 +0.47 (+0.53%) Closing price 03:59 PM EasternExtended Trading$88.82 +0.02 (+0.02%) As of 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Edwards Lifesciences Stock (NYSE:EW) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Edwards Lifesciences alerts:Sign Up Key Stats Today's Range$88.50▼$89.6650-Day Range$82.67▼$93.5952-Week Range$72.30▼$96.29Volume3.53 million shsAverage Volume2.98 million shsMarket Capitalization$51.14 billionP/E Ratio51.04Dividend YieldN/APrice Target$100.27Consensus RatingModerate Buy Company Overview Edwards Lifesciences Corporation (NYSE:EW) is a medical technology company focused on therapies for structural heart disease. Its products are designed to treat conditions affecting the heart valves and related cardiovascular structures, helping patients with diseases such as aortic stenosis, mitral regurgitation and tricuspid valve disorders. The company’s portfolio includes transcatheter aortic valve replacement systems, including its SAPIEN platform, as well as transcatheter mitral and tricuspid therapies and surgical heart valve products. Edwards also historically developed critical care monitoring technologies, although it has been concentrating its business increasingly on structural heart therapies. Founded in 1958 by engineer Miles Lowell Edwards, the company is headquartered in Irvine, California, and serves hospitals, physicians and patients in markets around the world. Edwards Lifesciences is led by President and Chief Executive Officer Bernard Zovighian.AI Generated. May Contain Errors. Read More Edwards Lifesciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks83rd Percentile Overall ScoreEW MarketRank™: Edwards Lifesciences scored higher than 83% of companies evaluated by MarketBeat, and ranked 71st out of 898 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingModerate Buy Consensus RatingEdwards Lifesciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.74, and is based on no strong buy ratings, 17 buy ratings, 6 hold ratings, and no sell ratings.Upside PotentialEdwards Lifesciences has a consensus price target of $100.27, representing about 12.9% upside from its current price of $88.81.Amount of Analyst CoverageEdwards Lifesciences has been the subject of 12 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Edwards Lifesciences' stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth13.00% Earnings GrowthEarnings for Edwards Lifesciences are expected to grow by 13.00% in the coming year, from $3.00 to $3.39 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Edwards Lifesciences is 51.04, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 42.41.Price to Earnings Ratio vs. SectorThe P/E ratio of Edwards Lifesciences is 51.04, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 213.90.Price to Earnings Growth RatioEdwards Lifesciences has a PEG Ratio of 2.32. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioEdwards Lifesciences has a P/B Ratio of 4.99. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Edwards Lifesciences' valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.57% of the float of Edwards Lifesciences has been sold short.Short Interest Ratio / Days to CoverEdwards Lifesciences has a short interest ratio ("days to cover") of 3.21, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Edwards Lifesciences has recently decreased by 11.90%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldEdwards Lifesciences does not currently pay a dividend.Dividend GrowthEdwards Lifesciences does not have a long track record of dividend growth. News and Social Media3.3 / 5News Sentiment1.20 News SentimentEdwards Lifesciences has a news sentiment score of 1.20. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.51 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Edwards Lifesciences this week, compared to 8 articles on an average week.Search Interest11 people have searched for EW on MarketBeat in the last 30 days. This is an increase of 57% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Edwards Lifesciences to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Company Ownership1.4 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Edwards Lifesciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $511,918.00 in company stock.Percentage Held by Insiders0.31% of the stock of Edwards Lifesciences is held by insiders.Percentage Held by Institutions79.46% of the stock of Edwards Lifesciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Edwards Lifesciences' insider trading history. Receive EW Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Edwards Lifesciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. EW Stock News HeadlinesEdwards Lifesciences (EW) Stock Looks Reasonable After Medicare TAVR ExpansionSeptember 18, 2026 | finance.yahoo.comHow Investors May Respond To Edwards Lifesciences (EW) Expanded TAVR Access And Transcatheter Valve AmbitionsSeptember 18, 2026 | finance.yahoo.comRothschilds and BlackRock are buying this high yield gold playMost stocks yield under 2%. Even gold stocks average less than 1%. One gold security, backed by one of the world's best mines, is yielding upwards of 10%. The Rothschilds, Vanguard, and BlackRock have already taken positions. With at least 8 more years of production ahead, early investors could see substantial total returns as prices start to move.September 22 at 1:00 AM | Golden Portfolio (Ad)Interventional Cardiology Devices Market by Type, End User - Global Forecast to 2031September 18, 2026 | finance.yahoo.comEdwards Lifesciences Corporation (EW) Presents at Deutsche Bank 2026 Healthcare Summit TranscriptSeptember 16, 2026 | seekingalpha.comInsider Selling: Edwards Lifesciences (NYSE:EW) VP Sells 619 SharesSeptember 12, 2026 | insidertrades.comEdwards Lifesciences (NYSE:EW) SVP Sells $49,536.64 in StockSeptember 1, 2026 | insidertrades.comEdwards Lifesciences (NYSE:EW) VP Annette Bruls Sells 2,644 Shares of StockAugust 29, 2026 | insidertrades.comSee More Headlines EW Stock Analysis - Frequently Asked Questions How have EW shares performed this year? Edwards Lifesciences' stock was trading at $85.26 on January 1st, 2026. Since then, EW shares have increased by 4.2% and is now trading at $88.8090. How were Edwards Lifesciences' earnings last quarter? Edwards Lifesciences Corporation (NYSE:EW) released its quarterly earnings data on Thursday, July, 23rd. The medical research company reported $0.78 EPS for the quarter, beating analysts' consensus estimates of $0.74 by $0.04. The company's quarterly revenue was up 13.6% on a year-over-year basis. Read the conference call transcript. When did Edwards Lifesciences' stock split? Shares of Edwards Lifesciences split on the morning of Friday, May 29th 2020.The 3-1 split was announced on Thursday, May 7th 2020. The newly created shares were distributed to shareholders after the closing bell on Monday, May 18th 2020. An investor that had 100 shares of stock prior to the split would have 300 shares after the split. Does Edwards Lifesciences have any subsidiaries? The following companies are subsidiaries of Edwards Lifesciences: CAS Medical Systems, Harpoon Medical, Valtech Cardio, CardiAQ Valve Technologies, BMEYE, Embrella Cardiovascular, Myocor, and more. Who are Edwards Lifesciences' major shareholders? Edwards Lifesciences' top institutional investors include BlackRock Inc. (10.21%), Wellington Management Group LLP (2.92%), Bank of New York Mellon Corp (2.45%) and Bank of America Corp DE (1.16%). Insiders that own company stock include Larry L Wood, Jean-Luc M Lemercier, Donald E Bobo Jr, Kieran Gallahue, Steven R Loranger, Bernard J Zovighian, Daniel J Lippis, Scott B Ullem, Catherine M Szyman, Daveen Chopra, Heisz Leslie Stone, Annette Bruls, Andrew M Dahl, Robert WA Sellers, Wayne Markowitz and Michael A Mussallem. View institutional ownership trends. How do I buy shares of Edwards Lifesciences? Shares of EW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Edwards Lifesciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Edwards Lifesciences investors own include Comcast (CMCSA), Chevron (CVX), Bristol Myers Squibb (BMY), Charles Schwab (SCHW), McKesson (MCK), Yum! Brands (YUM) and Toronto Dominion Bank (TD). Company Calendar Last Earnings7/23/2026Today9/22/2026Next Earnings (Estimated)10/29/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (1m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 EW's financial health is in the Green zone, according to TradeSmith. EW has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNYSE SectorHealthcare Industry Healthcare Equipment & Supplies Sub-IndustryHealthcare Equipment Current SymbolNYSE:EW CIK1099800 Webwww.edwards.com Phone(949) 250-2500Fax949-250-2525Employees16,000Year Founded1958Price Target and Rating Average Price Target for Edwards Lifesciences$100.27 High Price Target$110.00 Low Price Target$85.00 Potential Upside/Downside+12.9%Consensus RatingModerate Buy Rating Score (0-4)2.74 Research Coverage23 Analysts Profitability EPS (Trailing Twelve Months)$1.74 Trailing P/E Ratio51.04 Forward P/E Ratio29.60 P/E Growth2.32Net Income$1.07 billion Net Margins15.43% Pretax Margin21.77% Return on Equity15.68% Return on Assets12.05% Debt Debt-to-Equity Ratio0.06 Current Ratio4.52 Quick Ratio3.77 Sales & Book Value Annual Sales$6.07 billion Price / Sales8.43 Cash Flow$2.87 per share Price / Cash Flow30.98 Book Value$17.81 per share Price / Book4.99Miscellaneous Outstanding Shares575,800,000Free Float574,015,000Market Cap$51.14 billion OptionableOptionable Beta0.85 Social Links 7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NYSE:EW) was last updated on 9/22/2026 by MarketBeat.com Staff. From Our PartnersA councilman backed AI — then 13 bullets hit his front doorThirteen bullets hit an Indianapolis councilman's front door days after he backed a data center rezoning. Acro...Stansberry Research | Sponsored“Elon Is Not Showing This Publicly, But I Saw It”Elon Musk quietly filed a patent for a new AI invention while attention focused on the SpaceX IPO. Jeff Brown,...Brownstone Research | SponsoredIran War WARNING: Something Just ChangedA powerful Middle Eastern government is reportedly asking Trump for U.S. military help against Iran backed for...Banyan Hill Publishing | SponsoredDo this before December or regret itPorter Stansberry believes President Trump will use the December G20 Summit in Miami to unveil a radical monet...Porter & Company | SponsoredWhy Did Trump's Sons Put Money Into THIS Drone Company?Eric Trump and Donald Trump Jr. are reportedly backing an American drone manufacturer competing for a share of...Tim Sykes | SponsoredBezos… DOOMEDA single FCC filing hints Elon Musk is planning his biggest project yet - bigger than Tesla, SpaceX, and X com...Paradigm Press | SponsoredMajor Buy Alert Issued for September 30thKeith Kaplan has invested $17 million into his own AI research tools, building a platform now used by 180,000 ...TradeSmith | SponsoredGold did this exact thing in 1975… [then exploded]In 1975 the Fed raised rates and gold fell 50 percent. Headlines called the gold bull market dead. Instead gol...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Edwards Lifesciences Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Edwards Lifesciences With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
